Analyst Price Targets — CBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 8:52 pm | Stephen Willey | Stifel Nicolaus | $29.00 | $12.35 | StreetInsider | Crescent Biopharma Inc (CBIO) PT Lowered to $29 at Stifel |
| January 28, 2026 11:30 am | — | Piper Sandler | $35.00 | $11.27 | TheFly | Crescent Biopharma initiated with an Overweight at Piper Sandler |
| January 21, 2026 11:34 am | Brad Canino | Guggenheim | $35.00 | $13.98 | TheFly | Crescent Biopharma initiated with a Buy at Guggenheim |
| December 4, 2025 8:32 pm | Stephen Willey | Stifel Nicolaus | $32.00 | $12.99 | TheFly | Crescent Biopharma price target raised to $32 from $28 at Stifel |
| August 25, 2025 8:41 am | — | Jefferies | $26.00 | $14.70 | TheFly | Crescent Biopharma initiated with a Buy at Jefferies |
Latest News for CBIO
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's…
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company's…
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CBIO.
U.S. House Trading
No House trades found for CBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.